European pharmaceutical group warns that EU policymakers’ efforts to address issues fall “well short”
Europe’s share of the global investment in pharmaceutical R&D has shrunk, putting the bloc even further behind the US, an industry group has warned.
Pharmaceutical R&D expenditure in the US exceeded that in Europe by more than €20 billion ($20bn) in 2020, and the gap between the two has widened from just €2bn 20 years ago, the report from the European Association of Pharmaceutical Industries and Associations (Efpia) notes.